Is treatment with liraglutide efficient

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Endocrinología y Nutrición

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.ENDOEN.2014.03.003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Summary of product characteristics

  2016cited by this paper
• Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials

  2014cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials

  2013cited by this paper
• Costs, outcomes and challenges for diabetes care in Spain

  2013cited by this paper
• Standards of Medical Care in Diabetes—2013

  2012cited by this paper
• Recomendaciones 2012 de la Sociedad Española de Diabetes sobre la utilización de tiras reactivas para la medición de la glucemia capilar en personas con diabetes

  2012cited by this paper
• Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme

  2012cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes

  2012cited by this paper
• Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012influential reference
• The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

  2012influential reference
• Blood glucose control and quality of health care in non-insulin-treated patients with Type 2 diabetes in Spain: a retrospective and cross-sectional observational study

  2011cited by this paper
• Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study

  2011cited by this paper
• Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

  2010cited by this paper
• Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.

  2010cited by this paper
• Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes

  2010cited by this paper
• Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))

  2010cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Factors Predicting Glycemic Control in Middle-Aged and Older Adults With Type 2 Diabetes

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine

  2009cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial *

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Impact of the UKPDS—an overview

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

  2007cited by this paper
• Economic cost associated with type II diabetes in Spanish patients

  2006cited by this paper
• The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making

  2004cited by this paper
• Standards of medical care in diabetes.

  2004cited by this paper
• Direct health care costs of diabetic patients in Spain.

  2004cited by this paper
• Excess hospitalizations, hospital days, and inpatient costs among people with diabetes in Andalusia, Spain.

  2004cited by this paper
• El coste de la diabetes tipo 2 en España. El estudio CODE-2

  2002cited by this paper
• Qué es una tecnología sanitaria eficiente en España

  2002cited by this paper
• Los costes socioeconómicos de la diabetes mellitus

  2002cited by this paper
• Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*

  2002cited by this paper
• [What is an efficient health technology in Spain?].

  2002influential reference
• What role for statins? A review and economic model.

  1999cited by this paper
• Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds.

  1999cited by this paper
• Article: Health Economics

  year unknowninfluential reference

• Molecular identification, in vivo and in vitro activities of Calvatia gigantea (macro-fungus) as an antidiabetic agent

  2019cites this paper
• Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide

  2018cites this paper
• Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States

  2016cites this paper